Peter Lipsky News Today

/PRNewswire/ -- AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic...

A test for lupus patients from AMPEL could predict heart disease risk and provide decision support for prophylactic therapies.

/PRNewswire/ -- AMPEL BioSolutions today announced a genetic precision medicine test for lupus patients that could save lives by predicting heart disease...

CHARLOTTESVILLE, Va., Nov. 4, 2022 /PRNewswire/ -- AMPEL BioSolutions today announced a genetic precision medicine test for lupus patients that co...

/PRNewswire/ -- AMPEL BioSolutions today announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19...

/PRNewswire/ -- AMPEL BioSolutions today announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19...

A genomic test being developed by a Charlottesville, Va., company can predict a patient's risk of developing severe COVID-19, new research from UVA Health suggests.

WASHINGTON, Sept 19: Scientists in the US have developed a new genomic test that can predict a patient’s risk of developing severe COVID-19, an advance that could help doctors quickly begin tailored treatment. The test proved over 90 per cent accurate at predicting patient outcomes for COVID-19 among over two dozen patients in intensive care and 100 patients from publicly available data, the researchers said. The test, called CovGENE, analyses genes expressed in a person’s blood to d...

AMPEL BioSolutions has developed CovGENE, a new genomic test, that can detect and predict the severity of Covid-19 in patients.

/PRNewswire/ -- AMPEL BioSolutions today announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19...